Match!

The waves of Biotechnological Innovation in Medicine : Interfirm Cooperation Effects and a Venture Capital Perspective

Published on Dec 10, 2015
Kenneth Fernald1
Estimated H-index: 1
Abstract
markdownabstractAbstract Improving medicine and health is the ultimate purpose of biotechnological innovation, where basic science is used to develop new innovative diagnostics and therapeutics to significantly improve the lives of patients worldwide. Concurrently, for three stakeholder groups, the primary goal is to generate profitable business from biotechnological innovation. These stakeholders are ‘entrepreneurial’ biotech companies, venture capitalists and established pharmaceutical firms. This dissertation evaluates interfirm cooperation and venture capital investments, aiming to better understand how more biotechnological innovation can reach the market and which biotechnologies will revolutionize R&D productivity and global healthcare. The first studies show that alliances between established pharmaceutical firms and biotech companies outperform acquisitions of biotech companies by such firms, as these acquisition negatively affect innovation performance. Furthermore, alliances involve a risk-return trade-off in new product development, for biotech companies as technology suppliers. Moreover, for big pharma, alliances with- and acquisitions of biotech companies are both complementary innovation activities at higher levels of firms’ absorptive capacity. Regarding venture capital, the final studies show that venture capitalists fulfil a crucial role in the biopharmaceutical value chain. By investing in the right technologies and therapeutic areas, venture capitalists build for big pharma as they foresee big pharma’s future innovation demand. Simultaneously, venture capitalists create a technology push as visionary technological gatekeepers. Finally, the dissertation concludes that big pharma’s dominant logic and blockbuster paradigm have been the root cause of underutilized biotechnological innovation. It further proposes transformation towards a new organizational form for sustainable science-based business and effective exploitation of biotechnological innovation.
  • References (267)
  • Citations (4)
📖 Papers frequently viewed together
2015
1 Author (Kenneth Fernald)
201 Citations
2015
1 Author (Francesco Corea)
4 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References267
Newest
#1Kenneth Fernald (EUR: Erasmus University Rotterdam)H-Index: 4
#2Enrico PenningsH-Index: 19
Last. Eric ClaassenH-Index: 36
view all 3 authors...
The management and exploitation of biotechnological product innovation have proven to be more difficult than initially expected because the number of currently marketed biotechnological products is far from sufficient to counter deficits in pharmaceutical innovation. This study provides insight into the role of governance structures in interfirm cooperation and their effects on biotechnological product innovation and company success. Most of the existing literature regarding alliances and merger...
10 CitationsSource
#1Rebecca HendersonH-Index: 36
Neoclassical theory suggests that when an industry is shaken by radical technological change, incumbent firms will be replaced by entrants because entrants have greater strategic incentives to invest in radical innovation. Organizational theory suggests that incumbent firms fail in the face of radical innovation because they fall prey to inertia and complacency. I show that if organizational effects are significant, tests of neoclassical theory in isolation will yield spurious or noisy results. ...
656 Citations
#1Kenneth Fernald (EUR: Erasmus University Rotterdam)H-Index: 4
#2Ruud HoebenH-Index: 1
Last. Eric ClaassenH-Index: 36
view all 3 authors...
Venture capitalists (VCs) aim at trade sales as a preferred exit-strategy for biotechnology companies they invest in. Therefore, VCs pay close attention to the wishes of larger (bio)pharmaceutical acquirers. In this paper we explore VCs’ behavior and strategies by analyzing the technology fields and therapeutic areas in which they are invested most and which yield the highest returns by means of trade sales. The data show that VCs are by far most invested in oncology and this is also an area i...
4 CitationsSource
#1Esther PronkerH-Index: 8
#2Tamar Weenen (EUR: Erasmus University Rotterdam)H-Index: 8
Last. Albert D. M. E. Osterhaus (EUR: Erasmus University Rotterdam)H-Index: 113
view all 5 authors...
This exploratory qualitative article analyzes the potentially rate-limiting factors affecting value chain dynamics during adjuvanted-vaccine development. Adjuvants are considered immunostimulating substances that can be added to a vaccine. Although adjuvants have the potential to elicit adverse reactions, they also offer certain benefits. After approximately 90years of R&D, why have only four adjuvants been approved? Although ample literature is available describing the risks and benefits, it re...
5 CitationsSource
#1Dan H. Barouch (MIT: Massachusetts Institute of Technology)H-Index: 70
#2Louis J. PickerH-Index: 79
In this Opinion article, Dan Barouch and Louis Picker discuss recent data regarding the clinical development of novel serotype adenovirus and cytomegalovirus vaccine vectors for use in HIV-1 vaccines.
60 CitationsSource
#1Tamar Weenen (EUR: Erasmus University Rotterdam)H-Index: 8
#2Anne Jentink (VU: VU University Amsterdam)H-Index: 2
Last. Pierre Singer (TAU: Tel Aviv University)H-Index: 39
view all 7 authors...
Summary Background & aims A quantitative systematic identification and prioritization of unmet needs and research opportunities in relation to enteral nutrition was conducted by means of a tailor-made health research prioritization process. Methods The research objectives were reached by conducting qualitative interviews followed by quantitative questionnaires targeting enteral nutrition key opinion leaders (KOLs). (1) Define disease areas that deserve more research attention; (2) Rank importanc...
8 CitationsSource
#1Donald L. Drakeman (University of Cambridge)H-Index: 5
The biotech sector's record in originating high-priority medicines exceeds that of the pharmaceutical industry, its costs are lower and its products have comparable revenues.
7 CitationsSource
#1Samia N. Naccache (UCSF: University of California, San Francisco)H-Index: 24
#2Scot Federman (UCSF: University of California, San Francisco)H-Index: 19
Last. Charles Y. Chiu (UCSF: University of California, San Francisco)H-Index: 41
view all 26 authors...
Unbiased next-generation sequencing (NGS) approaches enable comprehensive pathogen detection in the clinical microbiology laboratory and have numerous applications for public health surveillance, outbreak investigation, and the diagnosis of infectious diseases. However, practical deployment of the technology is hindered by the bioinformatics challenge of analyzing results accurately and in a clinically relevant timeframe. Here we describe SURPI (“sequence-based ultrarapid pathogen identification...
244 CitationsSource
2013 was truly a year to remember for the public biotech sector, with the largest wave of IPOs since the 2000–2001 bubble.
16 CitationsSource
#1Stefano Denicolai (UNIPV: University of Pavia)H-Index: 9
#2Matias Ramirez (University of Sussex)H-Index: 11
Last. Joe Tidd (University of Sussex)H-Index: 27
view all 3 authors...
integration with and adaptation to internal capabilities and the exploitation of these novel combinations to create and capture value in new ways. However, studies focusing on the relationships among capabilities, BMI and firm performance are rare. In this paper, we adopt broader measures of internal and external knowledge, which include codified intangibles such as patents and copyrights, and examine the effects the combinations and interactions have on sales growth based on a dataset of 310 fi...
48 CitationsSource
Cited By4
Newest
What does it mean when a corporation claims to have a ‘license to operate’ in a local community? How does a member of an indigenous tribe make it to London to protest against a multinational mining company? How do managers perceive and speak about protest against their company and how does this discourse matter for social movement repression? First, I argue, based on a literature review, that responsiveness to local community needs has become an important factor influencing the ability of multin...
This PhD dissertation aims to advance scholarly and practical understanding regarding information processing and learning behaviors of organizational participants that influence their motivation to engage with, as well as their ability to manage, the ambidexterity paradox and individual exploration activities.
markdownabstractTraditionally, equity investors have relied upon the information reported in firms’ financial accounts to make their investment decisions. Due to the conservative nature of accounting standards, firms cannot value their intangible assets such as corporate culture, brand value and reputation. Investors’ efforts to collect such information have been hampered by the voluntary nature of Corporate Social Responsibility (CSR) reporting standards, which have resulted in the publication ...
markdownabstractScholars have assumed that social hierarchies, the rank ordering of individuals with respect to a valued social dimension within a team, are stable over time. However, hierarchies change and the more changeable they are, the more likely they are to lead to conflicts and have other negative interpersonal consequences. In this dissertation, I examine both the ups and the downs of hierarchy. Focusing on how and why people go up the hierarchy, I conducted a qualitative study of Dutch...
2 Citations